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Background: Pemetrexed is a key drug for the treatment of malig-
nant pleural mesothelioma. The intrapleural administration of pem-
etrexed might increase its efficacy and decrease its toxicity in
comparison with intravenous administration. The aim of this study
was to assess in an animal model the pharmacokinetics of pem-
etrexed administered intrapleurally compared with intravenously.
Methods: Thirty Wistar rats were randomly assigned to four groups
defined by route (intravenous or intrapleural) and dose (10 or 100
mg/kg) of pemetrexed. After pemetrexed administration, serial
plasma pemetrexed concentrations were analyzed by high perfor-
mance liquid chromatography to determine the maximum plasma
concentration (Cmax), the area under the plasma concentration-time
curve (AUC), and the total body clearance (CL).
Results: The Cmax was significantly lower after intrapleural versus
intravenous administration of 10 mg/kg pemetrexed (14.36 g/ml
versus 29.83 g/ml; p  0.008) or 100 mg/kg pemetrexed (70.64
g/ml versus 218.64 g/ml; p  0.001). At either dose, the AUC
and the CL did not significantly differ according to the route of
administration.
Conclusions: While intravenous and intrapleural administration of
pemetrexed yielded similar AUC and CL, the intrapleural route
yielded a significantly lower Cmax. As Cmax is a determinant of
pemetrexed toxicity, intrapleural administration might offer a means
of widening the effective therapeutic index of the drug by improving
tolerability. Future studies are needed to confirm this hypothesis in
malignant pleural mesothelioma patients.
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Malignant pleural mesothelioma (MPM) is an aggressivetumor with poor prognosis. While MPM is refractory to
most of treatments, recent data suggest a survival and quality
of life benefit for patients treated with chemotherapy. Among
the numerous drugs assessed in MPM, cisplatin is regarded as
the cornerstone of chemotherapy for this disease.1 The best
clinical results have been obtained with combinations of
cisplatin and antimetabolites, notably pemetrexed. This new
generation multitargeted antifolate exerts its action by dis-
rupting folate-dependent metabolic processes essential for
cell replication through inhibition of several enzymes.2 Since
a randomized phase III trial demonstrated a significant sur-
vival advantage for patients treated with cisplatin and pem-
etrexed compared with those treated with cisplatin alone,3
this combination has become a standard treatment for nonre-
sectable MPM.
Myelosuppression, as grade 3 and 4 neutropenia, was
the predominant dose-limiting toxicity reported in phase I
studies of pemetrexed.4–6 Consequently, the maximum toler-
ated dose (MTD) of pemetrexed was defined as 500 mg/m2.
However, even when administered intravenously at the MTD,
pemetrexed might not achieve sufficient pleural tissue pene-
tration to completely cure MPM.7
With the goal of improving the efficacy of chemother-
apy for patients with malignant pleural effusions, the intrapleu-
ral administration of several drugs has been assessed, notably:
cisplatin,8 liposome-entrapped cisplatin analog (L-NDDP),9
carboplatin,10 etoposide,11 and paclitaxel.12 Overall, the in-
trapleural administration of cytotoxics led to an intense and
extended exposure of pleural tissues to chemotherapy with
reduced systemic exposure. This route of administration
might consequently increase the treatment efficacy while
decreasing toxicity.
The intrapleural administration of pemetrexed has
never been studied. We hypothesized that, compared with the
intravenous route, intrapleural administration of pemetrexed
would both increase pleural tissue exposure to the drug and
alter systemic exposure to the drug. We tested the latter
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hypothesis in an animal model in which the pharmacokinetics
of intravenous and intrapleural pemetrexed were assessed.
MATERIALS AND METHODS
Animals
Wistar rats (Janvier, Le Genest-Saint-Isle, France) were
kept in the university rodent facility. They were housed in
designated rodent-storage modules in a temperature-con-
trolled room and had free access to water and food. The
present study was conducted in compliance with the recom-
mendations of the Federation of European Laboratory Animal
Science Associations. After completion of the experiment the
rats were killed by intraperitoneal injection of sodium pen-
tobarbital (120 mg/kg).
Study Design
Two different administration routes of pemetrexed (Al-
imta, Eli Lilly and Company, Indianapolis, IN) were com-
pared: the intravenous route and the intrapleural route. Fur-
thermore, two different doses of pemetrexed were studied: 10
and 100 mg/kg (approximately equivalent to 50 and 500
mg/m2 in humans, respectively).13 Rats were randomly as-
signed to 4 groups: 5 rats received 10 mg/kg of pemetrexed
intravenously (group 1), 5 rats received 100 mg/kg of pem-
etrexed intravenously (group 2), 10 rats received 10 mg/kg of
pemetrexed intrapleurally (group 3) and 10 rats received 100
mg/kg of pemetrexed intrapleurally (group 4).
Experimental Procedures
All rats were anesthetized with a first intraperitoneal
injection of ketamine (75 mg/kg) and acepromazine (2.5
mg/kg). Additional intraperitoneal injections were performed
to maintain general anesthesia throughout the entire proce-
dure. The rats breathed spontaneously and their body tem-
perature was maintained using blankets and heating lamps.
In groups 1 and 2, injection of pemetrexed was per-
formed via the jugular veins. Different dilutions of pem-
etrexed were used in the 2 groups to assure that the same
volume of solution was injected (approximately 0.5 ml). In
groups 3 and 4, rats were placed in a right lateral decubitus
position. A 3-mm pleural needle (Thorapix, Thiebaud, Mar-
gencel, France) was introduced in the left pleural cavity and
a pneumothorax was induced. A 2-mm rigid telescope (Rich-
ard Wolf Company, Knittlingen, Germany) was put inside the
pleural needle to confirm the existence of pneumothorax. The
intrapleural injection of pemetrexed was performed with a
Veress needle (Purple Surgical, Shenley, United Kingdom),
which was itself introduced inside the pleural needle. Pem-
etrexed was diluted such that both groups received the same
injection volume (approximately 1 ml). After intrapleural
injection of pemetrexed, gentle suction was applied to re-
expand the lung.
Before injection of pemetrexed, 0.5 ml of blood was
collected from one of the jugular veins (contralateral to the
pemetrexed injection site for groups 1 and 2). Additional 0.5
ml blood samples were harvested at 15, 30, 60, 120, and 180
minutes after chemotherapy administration. All blood sam-
ples were centrifuged and the plasma frozen at 80°C for
later determination of pemetrexed levels.
Pharmacokinetic Analysis
The plasma concentration of pemetrexed was deter-
mined by high performance liquid chromatography14 cali-
brated to a reference formulation of pemetrexed. For each
animal the pharmacokinetic parameters were calculated from
the plasma concentrations of pemetrexed using APIS soft-
ware version 4.17 (WGroupe, Pommiers la Placette, France).
The studied pharmacokinetic parameters were the maximum
plasma concentration (Cmax), the area under the plasma con-
centration-time curve (AUC), and the total body clearance
(CL). These last two parameters were estimated by extrapo-
lation of plasma pemetrexed concentrations to infinity.
Statistical Analysis
Descriptive and analytic statistics were performed us-
ing SPSS software version 13.0.1. The weight of rats was
compared between the four groups by the Mann-Whitney U
test. Using the same test, the pharmacokinetic parameters
were compared between the groups of animals receiving an
identical dose of pemetrexed by a different route of admin-
istration (group 1 versus group 3, group 2 versus group 4).
The differences were considered to be significant if p-values
were less than 0.05. The generalized linear model was used
for assessing correlations between pharmacokinetic parame-
ters in groups that received pemetrexed by the same route of
administration but at a different dose (group 1 versus group 2,
group 3 versus group 4).
RESULTS
Animals
The results of the present study were obtained by the
analysis of 30 animals which were randomized into 4 distinct
groups as previously described. The mean weight of the rats
was 478  118 g and there were no significant differences in
the mean weight of animals between the four groups (data not
shown).
Pharmacokinetics of Pemetrexed at 10 mg/kg
After intravenous injection of pemetrexed at 10 mg/kg
(group 1), the Cmax was achieved within the first 15 minutes
followed by rapid decline of plasma drug concentration. After
intrapleural injection (group 3), the plasma drug concentra-
tion increased moderately, remained stable during the first
hour and then decreased progressively (Figure 1). Concerning
pharmacokinetic parameters, the AUC and the CL did not
differ significantly between these groups, while the Cmax was
significantly higher in rats receiving pemetrexed intravenously
than in those receiving the drug intrapleurally (Table 1).
Pharmacokinetics of Pemetrexed at 100 mg/kg
The pharmacokinetic profiles of pemetrexed in group 2
and group 4 were similar to those of group 1 and group 3,
respectively, but shifted upwards (Figure 2). Again, the Cmax
was significantly higher in rats receiving pemetrexed intra-
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venously than in those receiving the drug intrapleurally, but
there was no significant difference in the AUC and the CL
between these 2 groups (Table 1).
Correlations Between Pharmacokinetic
Parameters and Pemetrexed Dose
When comparing the pharmacokinetic parameters be-
tween the groups receiving pemetrexed intravenously at 2
different doses (group 1 and group 2), we found a statistical
correlation between dose and the Cmax (adjusted R
2  0.866)
and the AUC (adjusted R2  0.853), but not the CL (adjusted
R2  0.124).
Concerning the groups receiving pemetrexed intrapleu-
rally (group 3 and group 4), there was a statistical correlation
between dose and the Cmax (adjusted R
2  0.653) and the
AUC (adjusted R2  0.702), but again, not the CL (adjusted
R2  0.036).
DISCUSSION
Pemetrexed is a major drug for MPM treatment. We
hypothesized that the intrapleural administration of pem-
etrexed would alter the systemic exposure to the drug com-
pared with intravenous administration. The aim of our pre-
FIGURE 1. Plasma concentrations
versus time after intravenous ad-
ministration of pemetrexed at 10
mg/kg (group 1, black line) and
after intrapleural administration of
pemetrexed at 10 mg/kg (group 3,
gray line).
TABLE 1. Pharmacokinetic Parameters of Pemetrexed in Rats
Receiving Pemetrexed Intravenously Versus Intrapleurally
Pemetrexed at 10 mg/kg Group 1 (IV)a Group 3 (IP)a p
Cmax (g/ml) 29.83  6.42 14.36  8.12 0.008
AUC (g/ml/h) 27.38  8.92 29.44  15.34 0.95
CL (liter/h) 0.19  0.08 0.21  0.11 0.68
Pemetrexed at 100 mg/kg Group 2 (IV)a Group 4 (IP)a p
Cmax (g/ml) 218.64  54.58 70.64  28.19 0.001
AUC (g/ml/h) 216.40  57.32 207.50  81.74 0.68
CL (liter/h) 0.20  0.08 0.28  0.15 0.25
a Values are mean  SD.
IV, intravenous administration; IP, intrapleural administration; Cmax, maximum
plasma concentration; AUC, area under the plasma concentration-time curve; CL, total
body clearance.
FIGURE 2. Plasma concentrations
versus time after intravenous ad-
ministration of pemetrexed at 100
mg/kg (group 2, black line) and
after intrapleural administration of
pemetrexed at 100 mg/kg (group
4, gray line).
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clinical study was to assess the pharmacokinetics of
intrapleural pemetrexed and to compare these with the phar-
macokinetics of intravenous pemetrexed. We studied pem-
etrexed at two different doses, and in both cases the Cmax was
significantly higher after intravenous than intrapleural admin-
istration, but neither the AUC nor the CL significantly dif-
fered according to the route of administration. Thus, the total
systemic exposure to the drug was similar between intrapleu-
ral and intravenous routes, but was more intense after the
latter. These differences in pharmacokinetics suggest that the
intrapleural administration might improve the patient toler-
ance to pemetrexed, as pemetrexed toxicity correlates with
not only the AUC, but also the Cmax.4
Our findings are in accord with those reported by
Pestieau et al.,14 who compared in rats the pharmacokinetics
of pemetrexed administered intraperitoneally versus intrave-
nously, and with the results of an experimental study, com-
paring intraperitoneal and intravenous administrations of cis-
platin in dogs.15 In humans, Lerza et al.10 compared the
pharmacokinetics of cisplatin and carboplatin administered
concurrently by intrapleural route to those of intravenous
administration. The Cmax of cisplatin and carboplatin were
significantly lower in case of intrapleural administration,
whereas the AUC were similar in both groups. In a phase I
study, the Cmax after intrapleural administration of 550
mg/m2 L-NDDP was four times inferior to the Cmax after
intravenous administration of 390 mg/m2 L-NDDP.9
While the rationale behind intrapleural chemotherapy is
the direct exposure of tumor cells to higher doses of cytotoxic
agents, intrapleural administration does not avoid systemic
drug exposure. In our study, the AUC did not differ between
the intrapleural and the intravenous administration of a given
pemetrexed dose. Nevertheless, this systemic delivery might
allow pemetrexed to diffuse into the inner core of tumor
tissue through tumor neovascularization. If so, the intrapleu-
ral administration of pemetrexed might combine two modes
of action: a direct exposure of the most superficial tumor cells
and an indirect exposure of the deeper tumor cells to chemo-
therapy.
The present study was not designed to directly assess
the pleural tissue exposure to pemetrexed, as there was no
reliable and technically feasible procedure for performing
such analyses. However, we compared the pharmacokinetic
parameters between the groups receiving pemetrexed by the
same route of administration at two different doses. Concern-
ing the intravenous administration, we showed that the CL
was not affected by the pemetrexed dose. Conversely, the
Cmax and the AUC varied in linear proportion to the dose.
Concerning the intrapleural route, the same relation was
observed, but the correlations were not strong enough to
exclude the possibility of saturation in pemetrexed transport
from the pleural cavity to systemic circulation. Such satura-
tion could be explained by several factors and might indi-
rectly reflect an increased pleural tissue exposure to pem-
etrexed when administered intrapleurally.
Based on pharmacokinetic results, our study supports
the hypothesis that the intrapleural administration of the
pemetrexed could improve patient tolerance to chemother-
apy. However, other approaches have been proposed to re-
duce pemetrexed side effects, notably a systematic supple-
mentation in folic acid and vitamin B12.16 Regardless, these
strategies are not incompatible and might be combined to
increase the patient tolerability to pemetrexed.
Although several studies have suggested some advan-
tages of the intrapleural route, no randomized trial has com-
pared intrapleural versus intravenous administration of che-
motherapy in terms of efficacy and toxicity, and intrapleural
chemotherapy has not reached current practice for MPM. By
contrast, numerous phase III studies have demonstrated the
superiority of intraperitoneal over intravenous chemotherapy
in the treatment of locally advanced ovarian cancer, and a
recent meta-analysis has confirmed this significant survival
benefit.17
Despite recent advances in intravenous chemotherapy,
MPM remains a disease with a poor prognosis which war-
rants further research. Before proceeding to a study of in-
trapleural pemetrexed in MPM patients, results of the present
research will be confirmed in a rat model with orthotopically
implanted MPM xenografts to evaluate our pharmacokinetic
findings under pathologic conditions. This system will be
used to determine the intrapleural pemetrexed dose bio-
equivalent to a standard intravenous dose of pemetrexed, and
to observe effects on xenograft growth and hematologic
toxicity. A follow-up phase I clinical study will determine the
MTD and dose-limiting toxicities of intrapleurally adminis-
tered pemetrexed.
In conclusion, compared with the intravenous route,
intrapleural administration of pemetrexed results in similar
AUC and CL, but significantly lower Cmax. Consequently,
intrapleural administration provides a less intense systemic
exposure to the drug than the intravenous route. Thus, in-
trapleural administration might offer a means of widening the
effective therapeutic index of the drug by improving patient
tolerance to pemetrexed. However, additional experimental
and clinical studies are needed to confirm this hypothesis in
MPM patients.
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